Opinion: Reexamination of Failed DMD Trial a Much-Needed Reckoning for FibroGen

A thorough reassessment of the confounders between FibroGen’s trials is necessary to salvage the company’s Duchenne Muscular Dystrophy program and regain investor confidence.